scholarly journals Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy

2014 ◽  
Vol 6 (9) ◽  
pp. 453 ◽  
Author(s):  
Salahuddin Mohammed ◽  
TezeraMoshago Berheto ◽  
DemissewBerihun Haile
Keyword(s):  
Antiretroviral Therapy ◽  
Loss To Follow Up ◽  
Living With Hiv ◽  
Hiv Aids

Determinants of loss to follow-up among people living with HIV on antiretroviral therapy in Nigeria

2021 ◽  
Vol 20 (1) ◽  
pp. 93-99
Author(s):  
Farouq Muhammad Dayyab ◽  
Fahad Mukhtar ◽  
Garba Iliyasu ◽  
Abdulrazaq Garba Habib
Keyword(s):  
Antiretroviral Therapy ◽  
People Living With Hiv ◽  
Loss To Follow Up ◽  
Living With Hiv

scholarly journals Factors of Loss to Follow-up Antiretroviral Therapy in Islanded Area

2018 ◽  
Vol 7 (2) ◽  
pp. 98-103
Author(s):  
Thomas Laga Boro ◽  
Rafael Paun ◽  
Marthen R Pellokila
Keyword(s):  
Antiretroviral Therapy ◽  
Self Efficacy ◽  
Random Sampling ◽  
Public Hospital ◽  
Simple Random Sampling ◽  
Case Control ◽  
People Living With Hiv ◽  
Loss To Follow Up ◽  
Hiv Aids

ABSTRACT Loss to follow-up of antiretroviral therapy is when PLWHA (People Living with HIV/AIDS) do not come for antiretroviral therapy for more than 3 months. This study aimed to determine the factors of loss to follow-up antiretroviral therapy for PLWHA at Prof. Dr. W. Z. Johannes Kupang Public Hospital where PLWHA with land, water and air transportation are served. This was a case control study with 66 samples of PLWHA. The samples underwent antiretroviral therapy in Prof. Dr.W.Z. Johannes Kupang Public Hospital from 2006 to 2016. Saturated sampling technique was done for cases group and simple random sampling was done for control group. Univariate and bivariate data analysis were done in this study. The result of bivariate analysis showed that there were association between intention (p = 0.004, OR = 4.667), self efficacy (p = 0.0001, OR = 7.875), action (p = 0.0001, OR = 45.000), transportation mode (p = 0.046, OR = 0.200), and transport costs (p = 0.0001, OR 19.333) and loss to follow-up antiretroviral therapy. It could be concluded that transportation and behavior were the major problems for the loss to follow up antiretroviral therapy in the islanded area.   Keywords: HIV/AIDS, antiretroviral therapy, loss to follow-up, islanded area   ABSTRAK Gagal follow-up antiretroviral therapy adalah  jika ODHA (Orang dengan HIV/AIDS) tidak menjalani terapi antireroviral lebih dari 3 bulan  terakhir. Penelitian ini bertujuan untuk mengetahui faktor-faktor gagal follow-up antiretroviral therapy pada ODHA di RSUD Prof. Dr. W. Z. Johannes Kupang yang melayani para ODHA dengan moda transportasi darat, air, dan udara. Desain penelitian ini adalah case control. Sampel sebanyak 66 ODHA yang menjalani antiretroviral therapy di RSUD Prof. Dr.W.Z. Johannes Kupang sejak tahun 2006 sampai 2016. Teknik pengambilan sampel yang digunakan adalah sampel jenuh untuk kelompok kasus dan simple random sampling untuk kelompok kontrol. Analisis data menggunakan prosentase untuk univariat dan bivariat. Hasil analisis bivariat menunjukkan ada pengaruh niat (p = 0,004, OR = 4,667), self efficacy (p = 0,0001, OR = 7,875), tindakan (p = 0,0001, OR = 45,000), moda transportasi (p = 0,046, OR = 0,200), dan biaya transportasi (p = 0,0001, OR 19,333) terhadap gagal  follow up terapi antiretroviral. Dapat disimpulkan bahwa masalah utama gagal follow up terapi antiretroviral di wilayah berkepulauan ini adalah transportasi dan perilaku.   Kata Kunci: HIV/AIDS,  terapi antiretroviral, gagal follow up, wilayah berkepulauan.

scholarly journals Cohort profile: The International epidemiology Databases to Evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019

2019 ◽  
Author(s):  
Frédérique Chammartin ◽  
Cam Ha Dao Ostinelli ◽  
Kathryn Anastos ◽  
Antoine Jaquet ◽  
Ellen Brazier ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Loss To Follow Up ◽  
Sub Saharan ◽  
Treat All ◽  
Living With Hiv ◽  
International Epidemiology

ABSTRACTPurposeThe objectives of the International epidemiology Databases to Evaluate AIDS (IeDEA) are to (i) evaluate the delivery of combination antiretroviral therapy (ART) in children, adolescents and adults in sub-Saharan Africa, (ii) to describe ART regimen effectiveness, durability and tolerability, (iii) to examine HIV-related comorbidities and co-infections, and (iv) to examine the pregnancy- and HIV-related outcomes of women on ART and their infants exposed to HIV or antiretroviral therapy in utero or via breastmilk.ParticipantsIeDEA is organized in four regions (Central, East, Southern and West Africa), with 240 treatment and care sites, six data centres at African, European and US universities, and almost 1.4 million children, adolescents and adult people living with HIV (PLWHIV) enrolled.Findings to dateThe data include socio-demographic characteristics, clinical outcomes, opportunistic events, treatment regimens, clinic visits and laboratory measurements. They have been used to analyse outcomes in people living with HIV-1 or HIV-2 who initiate ART, including determinants of mortality, of switching to second-line and third-line ART, drug resistance, loss to follow-up and the immunological and virological response to different ART regimens. Programme-level estimates of mortality have been corrected for loss to follow-up. We examined the impact of co-infection with hepatitis B and C, and the epidemiology of different cancers and of (multi-drug resistant) tuberculosis, renal disease and of mental illness. The adoption of “Treat All”, making ART available to all PLWHIV regardless of CD4+ cell count or clinical stage was another important research topic.Future plansIeDEA has formulated several research priorities for the “Treat All” era in sub-Saharan Africa. It recently obtained funding to set up sentinel sites where additional data are prospectively collected on cardiometabolic risks factors as well as mental health and liver diseases, and is planning to create a drug resistance database.

KARAKTERISTIK KLINIS PASIEN YANG MENERIMA TERAPI ARV DI RSUD KABUPATEN BULELENG

2020 ◽  
Vol 6 (2) ◽  
pp. 212-216
Author(s):  
I Gusti Ngurah Putu Candra ◽  
Dewi Aprelia Meriyani ◽  
Luh Putu Desy Puspaningrat ◽  
Yopita Triguno ◽  
Ni Kadek Ayu Tamara Widya Sari
Keyword(s):  
Loss To Follow Up ◽  
Hiv Aids

  ABSTRAK Latar Belakang Penyakit menular yang selalu memberikan dampak tidak hanya kesehatan tetapi social dan ekomoni adalha HIV/AIDS.Tujuan untuk mendeskripsikan kondisi klinis dan dmeografi pasien yang menerima terapi ARV.MetodePenelitian deskriptif dengan pendekatan secara kohort retrospektifmenggunakan data sekunder dari register kohort ARV dari tahun 2005-2015 (11 tahun terapi ARV). Analisis yang digunakan adalah analisis univariat menggunakan SPSS versi 17.Hasil Karakteristik klinis dan demografi pada odha yang menerima terapi ARV yaitu 45,32% dalam kondisi ambulatory, 75.42% mendapatkan regimen NNRTI jenis zidovudine, 75.82 % mendapatkan terapi regimen NRTI nevirapine, 79.66% pada kondisi stadium 3 dan 4, dengan klasifikasi umur produktif (< 40 tahun sebanyak 82.05%, sebagian besar berjenis kelamin laki-laki 62.96%, dan memiliki pengawas minum obat (PMO) sebesar 68.25%. Proporsi kematian sebesar  9.3 % (112 orang), LTFU (loss to follow up) 18.52% (223 orang), subsitusi regimen lini satu 9.88% (119 orang),rujuk keluar 1.83% (22 orang) dan yang masih dalam pengobatan sebesar 69.93% (842).Kesimpulan Pasien yang mengalami LTFU terbagi dalam beberapa kondisi yaitu LTFU dalam kondisi meninggal 3.07% (37 orang), LTFU dalam kondisi hidup 0.5% (6 orang), dan LTFU yang tidak diketahui kondisinya sebesar 14.95% (180 orang).Saran Monitoring dan evaluasi pada program pengobatan dilakukan secara berkelanjutan untuk meningkatkan konsistensi terapi yang dilakukan.  Kata Kunci : Karakteristik, Terapi, HIV/AIDS 

scholarly journals Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Anita Mesic ◽  
Alexander Spina ◽  
Htay Thet Mar ◽  
Phone Thit ◽  
Tom Decroo ◽  
...  
Keyword(s):  
Viral Load ◽  
Virological Failure ◽  
Antiretroviral Treatment ◽  
People Living With Hiv ◽  
First Line ◽  
Hiv Viral Load ◽  
Loss To Follow Up ◽  
History Of ◽  
Living With Hiv

Abstract Background Progress toward the global target for 95% virological suppression among those on antiretroviral treatment (ART) is still suboptimal. We describe the viral load (VL) cascade, the incidence of virological failure and associated risk factors among people living with HIV receiving first-line ART in an HIV cohort in Myanmar treated by the Médecins Sans Frontières in collaboration with the Ministry of Health and Sports Myanmar. Methods We conducted a retrospective cohort study, including adult patients with at least one HIV viral load test result and having received of at least 6 months’ standard first-line ART. The incidence rate of virological failure (HIV viral load ≥ 1000 copies/mL) was calculated. Multivariable Cox’s regression was performed to identify risk factors for virological failure. Results We included 25,260 patients with a median age of 33.1 years (interquartile range, IQR 28.0–39.1) and a median observation time of 5.4 years (IQR 3.7–7.9). Virological failure was documented in 3,579 (14.2%) participants, resulting in an overall incidence rate for failure of 2.5 per 100 person-years of follow-up. Among those who had a follow-up viral load result, 1,258 (57.1%) had confirmed virological failure, of which 836 (66.5%) were switched to second-line treatment. An increased hazard for failure was associated with age ≤ 19 years (adjusted hazard ratio, aHR 1.51; 95% confidence intervals, CI 1.20–1.89; p < 0.001), baseline tuberculosis (aHR 1.39; 95% CI 1.14–1.49; p < 0.001), a history of low-level viremia (aHR 1.60; 95% CI 1.42–1.81; p < 0.001), or a history of loss-to-follow-up (aHR 1.24; 95% CI 1.41–1.52; p = 0.041) and being on the same regimen (aHR 1.37; 95% CI 1.07–1.76; p < 0.001). Cumulative appointment delay was not significantly associated with failure after controlling for covariates. Conclusions VL monitoring is an important tool to improve programme outcomes, however limited coverage of VL testing and acting on test results hampers its full potential. In our cohort children and adolescents, PLHIV with history of loss-to-follow-up or those with low-viremia are at the highest risk of virological failure and might require more frequent virological monitoring than is currently recommended.

Sign in / Sign up

Export Citation Format

Share Document